KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to $7.6 billion.

  • Biomarin Pharmaceutical's Liabilities and Shareholders Equity rose 1114.66% to $7.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $29.2 billion, marking a year-over-year increase of 569.82%. This contributed to the annual value of $7.0 billion for FY2024, which is 215.35% up from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported Liabilities and Shareholders Equity of $7.6 billion as of Q3 2025, which was up 1114.66% from $7.5 billion recorded in Q2 2025.
  • Biomarin Pharmaceutical's 5-year Liabilities and Shareholders Equity high stood at $7.6 billion for Q3 2025, and its period low was $5.8 billion during Q1 2021.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $6.6 billion (2023), whereas its average is $6.6 billion.
  • Examining YoY changes over the last 5 years, Biomarin Pharmaceutical's Liabilities and Shareholders Equity showed a top increase of 2291.44% in 2021 and a maximum decrease of 293.3% in 2021.
  • Quarter analysis of 5 years shows Biomarin Pharmaceutical's Liabilities and Shareholders Equity stood at $6.0 billion in 2021, then grew by 6.17% to $6.4 billion in 2022, then rose by 7.32% to $6.8 billion in 2023, then rose by 2.15% to $7.0 billion in 2024, then grew by 8.96% to $7.6 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $7.6 billion for Q3 2025, versus $7.5 billion for Q2 2025 and $7.1 billion for Q1 2025.